Brian Blackburn, MD
Infectious Disease · Stanford, CANPI 1861542680
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,208 of the $1,521 with a category attached, or 79.5%. Stryker accounts for 87.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $731 and has fallen 87.3% since, to $93 in 2025.
Across 9 payments — averaging $168.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$1K
- Alphatec Spine, Inc$93
- Medtronic$89
- Viiv Healthcare Company$14
Across 2 payments — averaging $78,605 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$157K
What the payments were for
- Travel & lodging$1,20879%
- Food & beverage$31221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 5 | $1,325 |
| Alphatec Spine, Inc | 1 | $93 |
| Medtronic | 2 | $89 |
| Viiv Healthcare Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRITANIUM$1,188
How this compares
$1,521 in reported general payments places this provider in the 70th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Posaconazole | 12 | $9,168 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 24 | $870 |
| Rifampin | 15 | $847 |
| Amoxicillin | 15 | $80 |
| Isoniazid | 11 | $77 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Stanford
- Paul EckburgStanford$98K
- Michael HarbourStanford$89K
- Philip GrantStanford$27K
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- James McKinnellTorrance$762K
- Jay GladsteinLos Angeles$657K
- Tulika SinghOrange$654K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.